Oncologist

Papers
(The H4-Index of Oncologist is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
37 Cost-effectiveness of treatment sequences with front-line nivolumab+ipilimumab therapy vs immuno-oncology+tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcino150
8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial143
18 Unraveling the Impact of Tumor Microenvironment on Immunotherapy Response/Resistance in Human Sarcomatoid Clear Cell Renal Cell Carcinoma: Insights from a Novel Mouse Model108
55 Influence of gender on immunosurveillance in a novel mouse model of clear cell renal cell carcinoma90
Palliative Rehabilitation in Acute Inpatient Rehabilitation: Prognostic Factors and Functional Outcomes in Patients with Cancer88
Association BetweenCaregiver-OncologistDiscordance in Patient's Life Expectancy Estimates and Caregiver Perceived Autonomy Support by the Oncologist86
Clinical ethics consultation services: public-facing information on NCI-designated cancer center websites83
GBAS Regulates the Proliferation and Metastasis of Ovarian Cancer Cells by Combining with eEF1A178
Calls to action on lung cancer management and research75
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer74
“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management68
Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs65
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study65
Surgical De-Escalation in Medullary Thyroid Cancer: A Commentary63
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data61
Histologic Discordance Between Primary Tumor and Nodal Metastasis in Breast Cancer: Solving a Clinical Conundrum in the Era of Genomics58
The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)54
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis52
Classification of NK-large granular lymphocytic leukemia by CD56 expression50
56 Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship Confirms Best-in-class Potential of Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α Being Developed in Renal Cancer49
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options48
The Use of Natural Language Processing to Assess Social Support in Patients With Advanced Cancer47
Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma46
Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate44
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles43
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer42
Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy42
Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities38
Prevalence ofBRCA1andBRCA2Germline Mutations in Patients of African Descent with Early-Onset and Familial Colombian Breast Cancer38
Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience37
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma36
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation36
Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis36
Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer35
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay35
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial35
0.1495521068573